Drug Development

In this episode of the Drug Solutions Podcast, Jennifer Markarian, manufacturing reporter, talks about continuous manufacturing of oral solid-dosage drugs with Lawrence De Belder, executive consultant at Pharmatech Associates, a USP company.

An early formulation strategy for tablets that is simple and scalable is recommended to ensure fewer downstream problems.

The author introduces a practical approach to determining the best estimate of probability for passing multiple stage dissolution tests.

Although not easy to do, it is essential because excipients can affect drug-product safety and efficacy.

Experts discuss what data to consider when selecting a high-potential drug candidate and how AI can be harnessed in medicinal chemistry drug discovery.

3D cell cultures could provide key avenues to unlocking critical information.

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.

Under the two-year task order, ATCC will continue to support the DCEG MEAS program in receiving, processing, storing, analyzing, and distributing clinical specimens from different cancer types.

Sanofi and IGM Biosciences have announced a collaboration agreement for oncology, immunology, and inflammation targets.

Orion is planning to refocus its R&D efforts on the development of new proprietary products focused on cancer and pain.

Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.

DFE Pharma, Harro Höfliger, and Sterling have announced a partnership called Inhalation Together to provide formulation services for respiratory products.

Gamma Biosciences has announced an initiative through its subsidiary, Mirus Bio, to develop lipid-polymer nanocomplexes for improve mRNA delivery solutions.

physIQ and CellCarta are conducting a study to evaluate individual patient response to vaccination using wearable biosensors.

Sanofi is collaborating with Blackstone Life Sciences to accelerate the development of a treatment for multiple myeloma.

Sanofi and Seagen have entered an agreement to investigate three cancer targets.

Catalent has announced the completion of a $30 million project at its facility in Limoges, France focused on biopharmaceutical development and drug product manufacturing.

NIH has launched one of the first Phase 1 clinical trials to examine mRNA technology for HIV.

C4 Therapeutics has been granted orphan drug designation by FDA for CFT8634 for the treatment of soft tissue sarcoma.

SCG Cell Therapy has signed a collaboration agreement with A*STAR’s BTI to advance the development of antibodies for infectious diseases and cancer treatments.

Novo Nordisk will expand its existing research collaboration in novel delivery technologies with MIT and Brigham and Women’s Hospital.

Evonik has launched new EUDRATEC technology to improve solubility and performance of oral small molecules.

Oculis has gained exclusive global rights to neuroprotective drug candidate for glaucoma through a licensing agreement with Accure Therapeutics.

Researchers at McGill University have made advancements with a novel method for growing synthetic bone tissue.

FDA’s CDER continues to make rare diseases a priority with drug approvals and programming to speed therapeutic development.